6533b851fe1ef96bd12a8f98

RESEARCH PRODUCT

Modification of Hepatitis B Virus Infection by Recombinant Leukocyte Alpha A Interferon

K H Meyer Zum BüschenfeldeGeorg Hess

subject

MaleHBsAgImmunologyAlpha interferonAntibodies Viralmedicine.disease_causeInterferonmedicineHumansImmunology and AllergyHepatitis B e AntigensInterferon alfaHepatitis B virusHepatitis B Surface AntigensDose-Response Relationship Drugbiologybusiness.industryHIVvirus diseasesHomosexualityHematologyHepatitis Bmedicine.diseasebiology.organism_classificationVirologydigestive system diseasesHBeAgHepadnaviridaeInterferon Type IImmunologyCoinfectionDrug EvaluationFemalebusinessmedicine.drug

description

A defect in alpha interferon production in patients with chronic type B hepatitis offers a rationale principle for treating this disease with interferon. Two trials with interferon in chronic type B hepatitis indicate that this therapy achieves an elimination of HBsAg and HBeAg significantly higher than spontaneous. Our study and that of others indicate, however, that the response to interferon therapy is dependent on many variables including: the type of interferon, the interferon dose, duration of interferon treatment, sex, sexual preference in men and coinfection with other viruses. As of the multiple modes of action of interferon, a better understanding of viral replication, of the antiviral action of interferon in hepatitis B virus (HBV) infection and of the immunomodulatory action of interferon in HBV infection will help to improve the treatment of chronic HBV infection with interferon.

yearjournalcountryeditionlanguage
1986-09-01Immunobiology
https://doi.org/10.1016/s0171-2985(86)80106-1